<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089474</url>
  </required_header>
  <id_info>
    <org_study_id>DF6-CL-20-01</org_study_id>
    <nct_id>NCT05089474</nct_id>
  </id_info>
  <brief_title>A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE SURGICAL SYSTEM in Patients With Open-Angle Glaucoma</brief_title>
  <official_title>A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE SURGICAL SYSTEM in Patients With Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New World Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New World Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, nonrandomized, open label study to evaluate the safety and IOP lowering&#xD;
      effectiveness of the Streamline Surgical System, in patients with mild-to-moderate open angle&#xD;
      glaucoma undergoing cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, nonrandomized, open label study to evaluate the safety and IOP lowering&#xD;
      effectiveness of the Streamline Surgical System, a viscoelastic delivery device, in patients&#xD;
      with mild-to-moderate open angle glaucoma undergoing cataract surgery. This is a 12 month&#xD;
      study conducted outside the US. Approximately 60 subjects will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">February 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomized, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of unmedicated eyes with IOP reduction of &gt; 20% from Baseline at Month 12.</measure>
    <time_frame>12 months</time_frame>
    <description>Primary Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Assess intraoperative and post operative AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IOP change</measure>
    <time_frame>12 months</time_frame>
    <description>Mean IOP change in unmedicated IOP from baseline to M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of topical glaucoma medications</measure>
    <time_frame>12 months</time_frame>
    <description>Number of topical glaucoma medications used at screening compared to Month 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Streamline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Streamline Surgical System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Streamline Surgical System</intervention_name>
    <description>The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.</description>
    <arm_group_label>Streamline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and execute written informed consent&#xD;
&#xD;
          2. Males or female subjects at least 22 years of age.&#xD;
&#xD;
          3. Subjects qualifying for cataract surgery&#xD;
&#xD;
          4. Subjects diagnosed with mild to moderate open-angle glaucoma in at least one eye&#xD;
             currently treated with 1-3 topical IOP-lowering medications&#xD;
&#xD;
          5. Subjects with diagnosis of open-angle glaucoma in at least one eye with an unmedicated&#xD;
             IOP of 21-36 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child-bearing potential&#xD;
&#xD;
          2. Modified Shaffer angle grade &lt; 2&#xD;
&#xD;
          3. Patients with severe or advanced glaucoma&#xD;
&#xD;
          4. Intraocular surgery within the last 6 months or laser surgery within the last 3 months&#xD;
&#xD;
          5. BCVA worse than 20/80 in either eye&#xD;
&#xD;
          6. Patients with a previous peripheral iridotomy.&#xD;
&#xD;
          7. Ocular infection or inflammation within the last 6 months.&#xD;
&#xD;
          8. Any medication that would be contraindicated for a glaucoma surgical procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Theresa Landry, phD</last_name>
    <phone>817-480-7964</phone>
    <email>tlandry@newworldmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather P Reynolds, MS</last_name>
    <phone>8176881689</phone>
    <email>hreynolds@newworldmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica 20/20</name>
      <address>
        <city>San Jos√©</city>
        <state>CR</state>
        <zip>10108</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Orlich, MD</last_name>
      <phone>506-8375-8263</phone>
      <email>orlichclaudio@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nadja Dodero</last_name>
      <phone>506 8375 8263</phone>
      <email>ndodero@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro Laser</name>
      <address>
        <city>Santo Domingo</city>
        <state>DR</state>
        <zip>10124</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Batlle, MD</last_name>
      <phone>809-563-1324</phone>
      <phone_ext>1350</phone_ext>
      <email>jbatlle55@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Varela</last_name>
      <phone>809-563-1324</phone>
      <phone_ext>1350</phone_ext>
      <email>oftalmed@claro.net.do</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica Laser y Ultrasonido Ocular de Puebla</name>
      <address>
        <city>Puebla</city>
        <zip>72530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Lazcano, MD</last_name>
      <phone>52 55 1813 6386</phone>
      <email>drlazcano.glaucoma@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aimee Hernandez</last_name>
      <phone>52 55 1813 6386</phone>
      <email>aimeehdz20@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Costa Rica</country>
    <country>Dominican Republic</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Angle Glaucoma, IOP, viscoelastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

